FDA approves another in a new class of cholesterol drugs
Amgen's Repatha joins Sanofi's Praluent; but potency of medications raises a key question
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
THE US Food and Drug Administration (FDA) has approved the second drug in a novel class of powerful cholesterol-lowering medications.
The new drug, Repatha, made by Amgen, is intended for people with extremely high cholesterol levels and those with heart disease who cannot sufficiently lower their cholesterol levels with statins and other therapies. Repatha will cost US$14,100 per year.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
